1. Which of the following malignant hyperthermia (MH) symptoms is uniquely associated with succinylcholine use?
A. Tachycardia
B. Supraventricular arrhythmia
C. Jaw spasm
D. Ventricular arrhythmia
2. All of the following are core measures of the Surgical Care and Improvement Project (SCIP) except :
A. Use of prophylactic antibiotics appropriate for the patient's specific procedure
B. Initiation of prophylactic antibiotics within 1 hour before the first incision or within 2 hours for patients receiving vancomycin or fluoroquinolones
C. Continuation of prophylactic antibiotics for 24 hours after surgery completion or for 48 hours following intra-abdominal surgery
D. Discontinuation of prophylactic antibiotics within 24 hours after surgery completion or within 48 hours for cardiothoracic surgery
3. All of the following are patient-related factors that affect a person's risk of acquiring a surgical site infection (SSI) except :
A. Diabetes mellitus
B. Gender
C. Tobacco use
D. Corticosteroid use
4. Malignant hyperthermia should be treated with dantrolene 2 mg/kg, repeated every 5 minutes to a dose of 10 mg/kg or more if needed to stabilize the patient's respiratory symptoms. The total maximum dose should not exceed:
A. 16 mg/kg
B. 18 mg/kg
C. 30 mg/kg
D. 22 mg/kg
5. What is the most common cause of local anesthetic systemic toxicity (LAST)?
A. Inadvertent intravascular injection
B. Inappropriate dose
C. Inappropriate route of administration
D. Faulty injection technique
6. Malignant hyperthermia is caused by uncontrolled calcium release from the sarcoplasmic reticulum. The hydantoin-derivative dantrolene is used to treat MH. Dantrolene is classified as a:
A. Dihydropyridine calcium channel blocker
B. Non-dihydropyridine calcium channel blocker
C. Ryanidine receptor antagonist
D. Ryanidine receptor agonist
7. The primary goal of any medication's Risk Evaluation and Mitigation Strategy (REMS) is to:
A. Increase adherence
B. Decrease prescription drug diversion and abuse
C. Prevent the entry of high-risk medications to market
D. Manage a known or potential serious adverse risk
8. The appropriate dose of 20% lipid emulsion in the treatment of local anesthetic systemic toxicity is:
A. 1.5 mL/kg bolus over 1 minute followed by a continuous infusion of 15 mL/kg over a minimum of 30 minutes
B. 1.5 mL/kg bolus over 1 minute followed by a continuous infusion of 15 mL/kg over a minimum of 60 minutes
C. 1.0 mL/kg bolus over 1 minute followed by a continuous infusion of 10 mL/kg over a minimum of 30 minutes
D. 1.0 mL/kg bolus over 1 minute followed by a continuous infusion of 10 mL/kg over a minimum of 60 minutes
9. All of the following local anesthetics are classified as amides except :
A. Benzocaine
B. Lidocaine
C. Prilocaine
D. Bupivicaine
10. All of the following are symptoms regularly associated with LAST except :
A. CNS excitation
B. CNS depression
C. Autonomic instability
D. Cardiovascular instability
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. To what extent did the program meet objective #5?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
23. Will the information presented cause you to change your practice?
A. Yes
B. No
24. Are you committed to making these changes?
A. Yes
B. No
25. As a result of this activity, did you learn something new?
A. Yes
B. No
26. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology
I. Specialty Pharmacy
J. Industry/Manufacturing
27. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20
E. >20
